FDA approves gabapentin enacarbil after a twelve week trial.
The FDA has approved the restless legs syndrome drug gabapentin enacarbil (Horizant) to treat postherpetic neuralgia.
The drug is administered in one 600 mg dose for the first 3 days of treatment, followed by 600 mg doses twice daily on day four and onward, a statement from makers GlaxoSmithKline and XenoPort said.
Patients with renal impairment should have adjusted doses, the statement added.
Safety and efficacy for the new indication were evaluated in a 12-week ...
Continue Reading →MAR